Evercyte offers human cell lines for standardized in vitro bioassays and exosome production with therapeutic potential for tissue regeneration and targeted drug delivery. By extending cells' replicative lifespan via telomerase reactivation while preserving specific traits, Evercyte creates customized cell cultures and bioassays. Additionally, the company provides testing services to evaluate the efficacy, potency, and toxicity of drug candidates.
R&D:Evercyte specializes in producing and characterizing extracellular vesicles (EVs) for clinical use. By isolating and immortalizing human mesenchymal stromal or epithelial cells from various tissues, Evercyte creates standardized cell factories for clinical-grade EV production. To assess the biological activity of these EVs, Evercyte develops in vitro bioassays to test for anti-inflammatory, anti-fibrotic, neo-angiogenic, and anti-senescent effects.
Services:Evercyte as CRO, develops customized human cell lines from various tissues of healthy donors as well as from patients. The company also specializes in customized establishment of in vitro bioassays and offers testing services to evaluate the efficacy, potency, and toxicity of drug candidates or extracellular vesicles.